Skip to content
lifestyle.streetregister.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Alligator Bioscience
Notice of Extraordinary General Meeting in Alligator Bioscience AB
July 23, 2026
Alligator Discontinues Independent Development of Mitazalimab for a Strategic Refocus on the HLX22 Project, Announces a Rights Issue of Units of Approximately SEK 125.6 Million and Raises Bridge Loans
July 23, 2026
Alligator Announces First Patient Dosed in Investigator-Initiated Study of Intratumoral Mitazalimab in Early-Stage Breast Cancer
July 2, 2026
Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with HLX22
June 8, 2026
Alligator Bioscience Comments on Henlius Update on Long-Term Follow-Up Data for HLX22
May 25, 2026
Bulletin from The Annual General Meeting in Alligator Bioscience AB on 6 May 2026
May 23, 2026
Alligator Bioscience AB Reports Financial Results for The Period 1 January – 31 March 2026 and Provides a Business Update
May 22, 2026
←
Previous Page
1
2